<?xml version='1.0' encoding='utf-8'?>
<document id="27063071"><sentence text="Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects."><entity charOffset="98-106" id="DDI-PubMed.27063071.s1.e0" text="Warfarin" /></sentence><sentence text="Selexipag is a new orally available nonprostanoid prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension" /><sentence text=" Warfarin is commonly used in patients with pulmonary arterial hypertension"><entity charOffset="1-9" id="DDI-PubMed.27063071.s3.e0" text="Warfarin" /></sentence><sentence text=" Possible pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy individuals were investigated" /><sentence text="" /><sentence text="This was a double-blind, 2-way, 2-treatment crossover, Phase I study" /><sentence text=" Nineteen healthy men received a single dose of selexipag 400 μg or placebo on day 1, followed by selexipag 400 μg or placebo BID on days 2 to 12" /><sentence text=" A concomitant single dose of warfarin 20 mg was administered in the morning of day 8" /><sentence text="" /><sentence text="Both treatments were well tolerated" /><sentence text=" The most frequently reported adverse event was headache in both treatments" /><sentence text=" Geometric mean ratios and 90% CIs of the maximum international normalized ratio (geometric mean ratio = 0" /><sentence text="96; 90% CI, 0" /><sentence text="90-1" /><sentence text="03) and international normalized ratio AUC0-144h (geometric mean ratio = 0" /><sentence text="98; 90% CI, 0" /><sentence text="96-1" /><sentence text="00)] during treatment with warfarin and selexipag versus treatment with only warfarin were inside the reference limits of 0" /><sentence text="80 to 1" /><sentence text="25" /><sentence text=" The 90% CIs of the geometric mean ratios of AUC and Cmax for R- and S-warfarin during treatment with warfarin and selexipag versus treatment with warfarin alone were inside the reference range of 0" /><sentence text="80 to 1" /><sentence text="25" /><sentence text=" After repeated-dose administration of 400 μg selexipag, the AUC of selexipag and its active metabolite, ACT-333679, at steady state were not affected by a single dose of 20 mg warfarin" /><sentence text="" /><sentence text="Steady-state levels of selexipag and ACT-333679 after repeated doses of 400 μg selexipag had no influence on the warfarin pharmacodynamic variables" /><sentence text=" There was no pharmacokinetic interaction between selexipag and warfarin" /><sentence text="" /></document>